Trial Parameters
Brief Summary
Primary objectives: The purpose of this study is to identify single and composite biomarkers (from neuroimaging, electrophysiological, and non-imaging biological measures), clinical measures (from cognitive, psychometric, and behavioral test scores), and risk/protective factors (e.g., from medical history, socioeconomic status, coping, lifestyle) that can: 1. Predict antiseizure medication (ASM) treatment outcome, psychiatric, cognitive, or behavioral comorbidities, and quality of life in newly diagnosed epilepsy patients (Cohort II-III). 2. Predict a second epileptic seizure/epilepsy diagnosis and behavioral, cognitive, psychiatric dysfunction and quality of life in patients after a first epileptic seizure (Cohort I).
Eligibility Criteria
Inclusion Criteria for healthy subjects: * No history of current or past psychiatric or other major medical conditions Exclusion Criteria for healthy subjects: * Current or previous neurological disease, severe somatic disease, or consumption of medical drugs likely to influence the test results * Non-fluent in Danish or pronounced visual or auditory impairments * Current or past learning disability * Pregnancy or lactation (females) * Participation in experiments with radioactivity (\>10 mSv) within the last year or significant occupational exposure to radioactivity * Contraindications for MRI (pacemaker, metal implants, etc.) * Severe head injury * Alcohol or drug abuse * Drug use other than tobacco and alcohol within the last 30 days * Hash \> 50 x lifetime * Drugs \> 10 x lifetime (for each substance) * Current psychoactive medication * Any current or former primary psychiatric disorder (Axis I WHO ICD-10 diagnostic classification) Inclusion Criteria for patients: * Cohort I-II: Ag